top of page
Earth with Data Connections

Questors Techology

KRFI Questors Executive Summary
 

KRFI Ibogaine & Global Mental Health Security

​

The KRFI Ibogaine Global Mental Health Security Initiative advances safe, ethical, and regulated access to Ibogaine for substance use disorder (SUD) and mental health interventions. Through public-private partnerships, the program integrates WHO pre-qualified GMP manufacturing, blockchain-enabled supply chain security, and regional mental health policy coalitions. Ethical sourcing and Access and Benefit-Sharing (ABS) ensure indigenous knowledge and natural resources are respected and compensated. By strengthening clinical capacity, harmonizing regional policies, and ensuring QA/QC across the supply chain, this initiative provides a scalable model for global mental health security and responsible adoption of novel therapeutics.​

​​KRFI's principal for the Questors Technologies aim to support diverse biopharmaceutical areas for the innovation and the policy challenges to enhance and embrace advancement of the ibogaine and psychedelics industrial growth with integration of regulatory compliance for the new private public sector partnerships.

 

Global Mental Health Clinical Trial Management System (CTMS) works globally with Clinical Trial partners with Ibogaine for OUD/SUD therapeutics in diverse indications.  Natural Products Psychedelics (Psilocybin, Medical Cannabis, and other) entheogenic medicines for Trauma and Depression aims to share the CTMS in a hyperledger as a tools to advance the current scientific progress.   The Questors: Global Mental Health CTMS aims to partner with economic and sustainable Ibogaine treatments for OUD/SUD in the US FDA and global CTA regulatory agencies as a partnership for a regional trial.

​​​​

KRFI support the management of the Controlled substances in the mental health innovative research and efficiency of management through the technology support for the sustainable product development by sustainable managment.​  The KRFI aims to bring leveling up Ibogaine in a drug supply chain initiative to ensure accountability, sustainability, and optimized IP management. 

 

Key takeaways for the ibogaine and psychedelics research and Innovation:

​

Biodiversity Conservation and Access for Benefit Sharing (ABS)

​

Conservation comes with a progressive society, by conserving the indigenous traditions, and working with the ancestral knowledge of our universal entheogenic medicinal healing.

​

*Biodiversity biological material transfers and regional benefits resource management of indigenous Access for Benefit Sharing (ABS)-IP 

*Practical approaches to new challenges in drug accountability and oversight

*Progress in drug accountability and supply chain efficiency driven by intelligent Integrations & automation

*Review of emerging technologies and machine learning tools that will evolve drug

 

Become part of the PPP Accountability and supply management programs dedicated to the Ibogaine and Psychedelics for mental health therapeutics 

​

Join us in the unified agreements leading to successful implementation to protect and conserve indigenous knowledge and support a sustainable model for biodiversity protection of the indigenous land for the production of native plants. We are setting the foundation to uphold the standards of global conservation, for ibogaine policy.

Sign the protocols with us and announce the calls on the international communities to support the indigenous communities to secure the lands and protect their cultures and medicinal plants.

Salvus

An automated end-to-end Drug Safety Database, guarantees compliance and promotes alignment among global teams.

Crypta

A Literature Management Platform that detects the ICSR and automatically generates E2B R2/R3 XML. 

Ingest

Ingest structured and unstructured documents and create E2B R2 & R3 XML files.

AutoMedGen

Automatically generates high-quality, editable clinical, preclinical, regulatory and post-market documents

Qualitus

Unified Quality Management for Regulated Teams — Audit, CAPA & Training in one place

Rego

A global regulatory intelligence platform that support in identifying, evaluating, and implementing regulatory requirements.

​

FAQ


General Understanding

  1. Which regions or jurisdictions will the system need to comply with, and what regulatory standards are most relevant (e.g., FDA, EMA, GDPR, HIPAA)?

 

Integration and Interoperability

  1. Are there existing systems—such as EHRs, inventory management, or distribution platforms—that need to integrate with the blockchain?

  2. Will the solution need to interface with physical tracking technologies like barcodes, RFID tags, or IoT sensors?

 

Technical Preferences

  1. Are you open to using Hyperledger Fabric for this implementation, or do you have a preference for other frameworks like Quorum or Azure Confidential Ledger?

  2. What data points do you intend to store on-chain—manufacturing details, batch numbers, shipping status, expiry dates, etc.?

  3. Should the architecture be designed to support scalability across multi-center clinical trials or multiple geographic regions?

 

Compliance and Privacy

  1. Are there specific data privacy regulations (HIPAA, GDPR, etc.) that we should prioritize?

  2. Do you expect the system to support automated compliance reporting and third-party audit trails?

  3. Would you prefer to keep sensitive data (e.g., PHI) off-chain and store only encrypted references or logs on-chain?

 

Security and Access Control

  1. Should the system include advanced security features such as role-based access control and multi-factor authentication?

  2. Do you have defined roles and permission levels in mind for various stakeholders?

 

AI and Analytics

  1. Would you like to integrate AI/ML capabilities for functions such as predictive analytics or anomaly detection?

  2. Should analytics focus solely on supply chain data, or also extend to patient or clinical data?

 

Deployment and Infrastructure

  1. Do you prefer a fully cloud-hosted deployment (e.g., on Azure), or are you considering a hybrid or on-premises model?

  2. What is your expected timeline or ETA for deployment and testing?

 

Documentation and Handover

  1. Do you have existing documentation or system flowcharts that you can share with us?

  2. Would your team require training sessions and detailed handover documentation as part of the delivery?

​

Contact us: Info@krfi.org

​

Sign up for a membership to join as a private public sector partner for the Global Mental Heatlth Security Fund and Become Our Task Force Leader 

bottom of page